AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more ...

Each year, a single cow can belch about 200 pounds of methane. The powerful greenhouse gas is 27 times more potent at ...

A Kingston research team has created a patented 3D-printed surgical biopsy tool that allows scientists to map and study ...

Researchers have mapped the regulatory elements that control the FOXP3 gene, which is implicated in maintaining balance in ...

With the global technical textiles market heading toward $200B by 2030 , KBLB’s timing could enable early adoption and prototype work for 2026 procurement cycles, especially in high-performance and ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

The up to $1.4M collaboration will enable manufacturing “universal” islets containing a drug-inducible safety feature designed to make curative therapies accessible without the need for chronic ...

The food biotechnology market is projected to grow substantially over the next decade, rising from an estimated USD 32.5 ...

It’s not often that a news story unsettles me in the way one I spotted in this very newspaper last week has done. Apparently, ...

OpenAI chief executive Sam Altman and his husband are now backing a contentious new venture that intends to use genetic engineering on babies to eliminate inherited diseases. The start-up, Preventive, ...